𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cholinergic abnormalities in Alzheimer's disease: are there new targets for drug development?

✍ Scribed by Lisa R. Fodero; David H. Small

Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
167 KB
Volume
56
Category
Article
ISSN
0272-4391

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease characterized by cognitive impairment and behavioral changes. Cholinesterase inhibitors are currently the drugs of choice for the treatment of AD. However, alternatives to cholinesterase inhibitors such as muscarinic and nicotinic agonists are also being investigated for more effective treatment of AD. This review examines the role of cholinesterase inhibitors and the potential of other therapeutic agents which target nicotinic and muscarinic receptors for the treatment of AD. Drug Dev. Res. 56:369–379, 2002. Β© 2002 Wiley‐Liss, Inc.

πŸ“œ SIMILAR VOLUMES

The economic consequences of Alzheimer's
The economic consequences of Alzheimer's disease in the context of new drug developments
✍ Martin Knapp; David Wilkinson; Rachel Wigglesworth πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 165 KB πŸ‘ 3 views

The first national symptomatic treatment for Alzheimer's disease has received a very mixed and perhaps ageist reception from purchasers of health care in the UK. This is largely because detailed information on the long-term effects of this class of drugs is scarce. However, by looking at the publish